MedTrace Logo

Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose

NCT02514746 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 561

Last updated 2020-10-19

Study results available
· View outcomes & findings →

Summary

This study aims to understand the persistence of the Japanese encephalitis (JE) antibody response in previously vaccinated children. The proposed study will enrol Bangladeshi children who had previously participated in a lot to lot consistency study (JEV05; NCT01567865) of JE live attenuated SA 14-14-2 vaccine (CD-JEV).

Conditions

  • Encephalitis, Japanese

Interventions

BIOLOGICAL

Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine

0.5 mL subcutaneous injection

Sponsors & Collaborators

  • International Centre for Diarrhoeal Disease Research, Bangladesh

    collaborator OTHER

  • PATH

    lead OTHER

Principal Investigators

  • K Zaman, PhD, MPH, MBBS · International Centre for Diarrhoeal Disease Research, Bangladesh

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
43 Months
Max Age
51 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-30
Primary Completion
2016-12-15
Completion
2017-01-12

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02514746 on ClinicalTrials.gov